The fight against cancer received a multi-million dollar boost from GEM Global Yield, an investment vehicle operated by $3.4 billion Luxembourg-based alternative assets firm Global Emerging Markets.
GEM entered into an ongoing commitment to purchase up to $90 million in common shares of NuView Life Sciences, a Park City, Utah-based developer of in vitro cancer diagnostic and theranostics -- that is, products that can diagnose as well as treat disease.
NuView plans to use the funds to complete a 600-patient in vitro double-blind clinical trial to advance its NV-VPAC1 . . .
Continue Reading
Not a subscriber yet? Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
